Key targets of SAG treatment for melanoma are enriched in the phosphatidylinositol 3-kinase/AKT pathway 42, and activating transcription factor-3 inhibits melanoma growth by downregulating the extracellular regulated protein kinase and AKT levels 43. This evidence concerns the gene ATF3 and melanoma.